We outline the 3 key components of a good value proposition, designed to demonstrate the value of ne...
Read moreInnovative therapies for rare diseases may only be available in a select number of countries in Euro...
Read moreThe introduction of new medicines in England requires the cooperation of industry and the NHS.
Read moreNICE is increasing opportunities for patient engagement by simplifying the process and increasing pa...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read morePatents are usually only valid for around 20 years however, as patenting occurs early in the R&D pro...
Read moreReal-world evidence (RWE) refers to clinical and economic evidence which has been derived from the a...
Read moreIntegrated Care Systems (ICS) have been designed to enable health and care organisations to join for...
Read moreUntil June 30th, 2021, the FDA in the US and European Medicine Agency in Europe have launched 32 and...
Read moreNICE’s remodel plans focus on delivering faster and fairer access to treatments by optimising appr...
Read more